THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [9.4]-C83 ID: TIP-MED-000353

Fluticasone Propionate (ICS

Active Ingredient / Scientific Identity: Fluticasone Propionate • Class: Slow-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour Bronchodilator with Slow 15–30 Minute Onset)

⚖️ Compare Profile
Generic / Entity NameFluticasone Propionate (ICS ([9.4]-C83)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSlow-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour Bronchodilator with Slow 1
Available Dosage FormsSeroflo pMDI Inhaler: Salmeterol 25 mcg + Fluticasone Propionate 125 mcg or 250 mcg per puff; Seroflo Rotacaps
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: No dose adjustment needed. Hepatic: Both salmeterol and fluticasone undergo extensive hepatic CYP3A4 clearance; monito
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Fluticasone Propionate (ICS (TIP-MED-000353, Reference Code [9.4]-C83) is classified under Respiratory, Asthma, COPD & Allergy Medicines (Ch 09) as a Slow-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour Bronchodilator with Slow 15–30 Minute Onset). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [9.4] (Salmeterol Xinafoate (in Fixed-Dose Combination with Fluticasone Propionate)). Representative Indian Market Examples (Edition 2.7 Ch 09 [9.4], p. 115): Dispensed in India as an ICS + LABA Fixed-Dose Combination (Salmeterol + Fluticasone Propionate): Seroflo (Cipla—100, 250, 500), Seretide Accuhaler/Evohaler (GSK), Airtec-SF, Combitide (Sun), Fluticort-S, Digihaler-SF — Strengths & Dosage Forms: Seroflo pMDI Inhaler: Salmeterol 25 mcg + Fluticasone Propionate 125 mcg or 250 mcg per puff; Seroflo Rotacaps / Autohaler / Accuhaler (DPI): Salmeterol 50 mcg + Fluticasone Propionate 100 mcg, 250 mcg, or 500 mcg
Co-indexed constituent under primary monograph [9.4] (Salmeterol Xinafoate (in Fixed-Dose Combination with Fluticasone Propionate)). Representative Indian Market Examples (Edition 2.7 Ch 09 [9.4], p. 115): Dispensed in India as an ICS + LABA Fixed-Dose Combination (Salmeterol + Fluticasone Propionate): Seroflo (Cipla—100, 250, 500), Seretide Accuhaler/Evohaler (GSK), Airtec-SF, Combitide (Sun), Fluticort-S, Digihaler-SF — Strengths & Dosage Forms: Seroflo pMDI Inhaler: Salmeterol 25 mcg + Fluticasone Propionate 125 mcg or 250 mcg per puff; Seroflo Rotacaps / Autohaler / Accuhaler (DPI): Salmeterol 50 mcg + Fluticasone Propionate 100 mcg, 250 mcg, or 500 mcg
Dosage Forms & Available Strengths:
Seroflo pMDI Inhaler: Salmeterol 25 mcg + Fluticasone Propionate 125 mcg or 250 mcg per puff; Seroflo Rotacaps / Autohaler / Accuhaler (DPI): Salmeterol 50 mcg + Fluticasone Propionate 100 mcg, 250 mcg, or 500 mcg
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Slow-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour Bronchodilator with Slow 15–30 Minute Onset) acting on target receptor/enzyme pathways in Respiratory, Asthma, COPD & Allergy Medicines (Ch 09): clinical efficacy is mediated via Slow-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour Bronchodilator with Slow 15–30 Minute Onset) for Regular maintenance controller therapy for persistent Bronchial Asthma and severe COPD with history of repeated exacerbations..

4. Therapeutic Indications & Evidence-Supported Uses

  • Regular maintenance controller therapy for persistent Bronchial Asthma and severe COPD with history of repeated exacerbations

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: pMDI: 2 puffs twice daily (every 12 hours, delivering 50 mcg salmeterol/dose). Rotacap / Accuhaler DPI: 1 capsule/blister (50 mcg salmeterol) twice daily (every 12 hours). Maximum dose: 50 mcg Salmeterol twice daily! Follow physician prescription.

Administration & Meal Timing: Inhaled: Independent of food; rinse mouth and spit after every dose. | Strictly twice daily (every 12 hours: morning and night).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [9.4].
Metabolism & Biotransformation:
Renal: No dose adjustment needed. Hepatic: Both salmeterol and fluticasone undergo extensive hepatic CYP3A4 clearance; monitor closely in moderate-to-severe liver disease.
Elimination & Renal Adjustment:
Renal: No dose adjustment needed. Hepatic: Both salmeterol and fluticasone undergo extensive hepatic CYP3A4 clearance; monitor closely in moderate-to-severe liver disease.
Hepatic Impairment Considerations:
Renal: No dose adjustment needed. Hepatic: Both salmeterol and fluticasone undergo extensive hepatic CYP3A4 clearance; monitor closely in moderate-to-severe liver disease.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • CRITICAL DIFFERENCE FROM FORMOTEROL (FORACORT): Salmeterol has a SLOW onset of action (takes 15 to 30 minutes to begin opening airways, peaking at 2–3 hours)! Therefore, Seroflo MUST NEVER BE USED AS AN ACUTE RESCUE RELIEVER during a sudden asthma attack! Patients using Seroflo MUST always carry a separate fast-acting reliever inhaler (such as Salbutamol [Asthalin]) for sudden breathlessness! Never exceed twice-daily dosing.

Key Clinical Precautions: Renal: No dose adjustment needed. Hepatic: Both salmeterol and fluticasone undergo extensive hepatic CYP3A4 clearance; monitor closely in moderate-to-severe liver disease.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Oropharyngeal candidiasis (thrush) and hoarseness of voice (fluticasone has high topical potency and throat deposition if a spacer and mouth rinse are not used), fine tremor, palpitations, headache, muscle cramps.
  • Increased incidence of bacterial Pneumonia in elderly COPD patients (particularly with the high 500 mcg fluticasone strength), systemic steroid effects (adrenal suppression, cataracts, osteoporosis), hypokalaemia, arrhythmias in IHD patients, paradoxical bronchospasm.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Potent CYP3A4 Inhibitors (Ritonavir, Ketoconazole, Itraconazole, Clarithromycin): STRICTLY AVOID! Ritonavir and itraconazole increase plasma Fluticasone levels >100-fold (causing severe Cushing's syndrome and adrenal crisis) and increase Salmeterol levels (causing QTc prolongation and ventricular arrhythmias)
    • Non-selective beta-blockers antagonise salmeterol
    • Diuretics/theophylline increase hypokalaemia

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [9.4].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: 1. Warn every patient on Seroflo: 'Seroflo is your slow-acting 12-hour daily shield—it takes 20 minutes to start working, so NEVER puff extra Seroflo during a sudden breathless attack! Keep your blue Asthalin inhaler handy for sudden rescue.' 2. Note that pMDI requires 2 puffs to deliver 50 mcg salmeterol (with a 30–60 second pause between puff 1 and puff 2), whereas Rotacaps require 1 capsule inside the Rotahaler. 3. Always rinse mouth, gargle, and spit water after every use!
    • Meal & Clock Timing Instruction: Inhaled: Independent of food; rinse mouth and spit after every dose. (Strictly twice daily (every 12 hours: morning and night).)
    • Missed Dose Protocol: Take the next scheduled dose at the normal time; never take extra puffs of Seroflo for acute breathlessness.
    • Geriatric Dispensing Pearl: In elderly COPD patients using high-strength Seroflo 250 or 500, watch closely for recurrent lower respiratory infections/pneumonia, oral thrush, cataracts, and easy skin bruising; verify if the chest physician can step down steroid dose or use LAMA/LABA dual bronchodilation if eosinophils are low.

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Seroflo pMDI Inhaler: Salmeterol 25 mcg + Fluticasone Propionate 125 mcg or 250 mcg per puff; Seroflo Rotacaps / Autohaler / Accuhaler (DPI): Salmeterol 50 mcg + Fluticasone Propionate 100 mcg, 250 mcg, or 500 mcg

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.